About Surmodics (NASDAQ:SRDX)
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Adhesive
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:SRDX
- CUSIP: 86887310
- Web: www.surmodics.com
- Market Cap: $410.61 million
- Outstanding Shares: 13,109,000
- 50 Day Moving Avg: $29.98
- 200 Day Moving Avg: $26.30
- 52 Week Range: $21.90 - $32.80
Sales & Book Value:
- Trailing P/E Ratio: 67.43
- Foreward P/E Ratio: -1,031.67
- P/E Growth: 10.00
- Annual Revenue: $71.21 million
- Price / Sales: 5.70
- Book Value: $8.34 per share
- Price / Book: 3.71
- EBITDA: $15.57 million
- Net Margins: 8.66%
- Return on Equity: 7.28%
- Return on Assets: 6.01%
- Current Ratio: 7.65%
- Quick Ratio: 7.18%
- Average Volume: 35,260 shs.
- Beta: 0.86
- Short Ratio: 13.54
Frequently Asked Questions for Surmodics (NASDAQ:SRDX)
What is Surmodics' stock symbol?
Surmodics trades on the NASDAQ under the ticker symbol "SRDX."
How were Surmodics' earnings last quarter?
Surmodics, Inc. (NASDAQ:SRDX) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $0.09 EPS for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.10. The company earned $17.80 million during the quarter, compared to the consensus estimate of $15.98 million. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. The company's quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.37 EPS. View Surmodics' Earnings History.
When will Surmodics make its next earnings announcement?
What guidance has Surmodics issued on next quarter's earnings?
Surmodics issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $0.29-0.39 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.19. The company issued revenue guidance of $70.0-72.0, compared to the consensus revenue estimate of $67.59 million.
Where is Surmodics' stock going? Where will Surmodics' stock price be in 2017?
3 brokers have issued 12 month target prices for Surmodics' stock. Their forecasts range from $40.00 to $40.00. On average, they anticipate Surmodics' stock price to reach $40.00 in the next year. View Analyst Ratings for Surmodics.
Who are some of Surmodics' key competitors?
Some companies that are related to Surmodics include PetIQ (PETQ), China Cord Blood Corporation (CO), Eagle Pharmaceuticals (EGRX), Cytokinetics, Incorporated (CYTK), Revance Therapeutics (RVNC), AtriCure (ATRC), Alder BioPharmaceuticals (ALDR), CRISPR THERAPTC (CRSP), Keryx Biopharmaceuticals (KERX), La Jolla Pharmaceutical Company (LJPC), ZIOPHARM Oncology (ZIOP), CytomX Therapeutics (CTMX), LeMaitre Vascular (LMAT), Flexion Therapeutics (FLXN), PTC Therapeutics (PTCT), Community Health Systems (CYH), Vanda Pharmaceuticals (VNDA) and Coherus BioSciences (CHRS).
Who are Surmodics' key executives?
Surmodics' management team includes the folowing people:
- Susan E. Knight, Independent Chairman of the Board
- Gary R. Maharaj, President, Chief Executive Officer, Director
- Andrew D. C. LaFrence, Vice President of Finance and Information Systems and Chief Financial Officer
- Thomas A. Greaney, Executive Vice President of Medical Devices
- Bryan K. Phillips, Senior Vice President - Legal and Human Resources, General Counsel & Secretary
- Charles W. Olson, Senior Vice President of Commercial and Business Development, Medical Devices
- Joseph J. Stich, Vice President, General Manager - In Vitro Diagnostics
- Timothy J. Arens, Vice President - Corporate Development and Strategy
- Gregg S. Sutton, Vice President - Research & Development
- Lisa Wipperman Heine, Director
How do I buy Surmodics stock?
Shares of Surmodics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Surmodics' stock price today?
MarketBeat Community Rating for Surmodics (NASDAQ SRDX)MarketBeat's community ratings are surveys of what our community members think about Surmodics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Surmodics stock can currently be purchased for approximately $30.95.
Consensus Ratings for Surmodics (NASDAQ:SRDX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 2 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$40.00 (29.24% upside)|Consensus Price Target History for Surmodics (NASDAQ:SRDX)
Analysts' Ratings History for Surmodics (NASDAQ:SRDX)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/14/2017||Lake Street Capital||Initiated Coverage||Buy -> Buy||$40.00||Medium|
|11/21/2016||Barrington Research||Downgrade||Outperform -> Market Perform||N/A|
|10/6/2016||Sidoti||Downgrade||Buy -> Neutral||$33.00||N/A|
Earnings History for Surmodics (NASDAQ:SRDX)Earnings History by Quarter for Surmodics (NASDAQ SRDX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q3 2017||($0.01)||$0.09||$15.98 million||$17.80 million||View||Listen|
|4/27/2017||Q2 2017||$0.07||$0.05||$16.21 million||$17.50 million||View||N/A|
|2/2/2017||Q117||$0.09||$0.19||$15.81 million||$17.80 million||View||Listen|
|11/16/2016||Q4 2016||$0.09||$0.26||$16.09 million||$18.20 million||View||Listen|
|7/28/2016||Q316||$0.12||$0.37||$16.31 million||$19.97 million||View||Listen|
|5/2/2016||Q2||$0.09||$0.20||$14.71 million||$16.70 million||View||Listen|
|1/28/2016||Q116||$0.17||$0.38||$14.58 million||$16.50 million||View||Listen|
|11/10/2015||Q415||$0.19||$0.30||$15.30 million||$17.40 million||View||Listen|
|8/5/2015||Q315||$0.21||$0.26||$14.86 million||$15.90 million||View||Listen|
|4/30/2015||Q2||$0.20||$0.19||$14.09 million||$14.40 million||View||Listen|
|1/29/2015||Q414||$0.21||$0.25||$14.30 million||$14.20 million||View||Listen|
|11/6/2014||Q314||$0.25||$0.26||$14.90 million||$15.30 million||View||N/A|
|7/31/2014||Q214||$0.23||$0.27||$14.84 million||$14.62 million||View||Listen|
|5/1/2014||Q114||$0.20||$0.22||$14.40 million||$13.60 million||View||Listen|
|1/30/2014||Q413||$0.21||$0.21||$14.15 million||$13.90 million||View||Listen|
|11/5/2013||Q313||$0.22||$0.26||$14.32 million||$14.30 million||View||Listen|
|7/31/2013||Q3 2013||$0.21||$0.22||$15.03 million||$14.29 million||View||Listen|
|5/7/2013||Q2 2013||$0.21||$0.20||$13.92 million||$13.70 million||View||Listen|
|1/30/2013||Q1 2013||$0.18||$0.29||$13.63 million||$13.85 million||View||Listen|
|11/6/2012||Q412||$0.17||$0.17||$13.83 million||$13.80 million||View||N/A|
Earnings Estimates for Surmodics (NASDAQ:SRDX)
2017 EPS Consensus Estimate: $0.18
2018 EPS Consensus Estimate: $0.20
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Surmodics (NASDAQ:SRDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Surmodics (NASDAQ:SRDX)
Insider Ownership Percentage: 6.40%Insider Trades by Quarter for Surmodics (NASDAQ:SRDX)
Institutional Ownership Percentage: 84.85%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/15/2017||Charles W Olson||VP||Sell||801||$27.85||$22,307.85|| |
|9/11/2017||Joseph J. Stich||VP||Sell||1,000||$27.28||$27,280.00|| |
|8/7/2017||Gary R Maharaj||CEO||Sell||5,000||$25.75||$128,750.00|| |
|7/3/2017||Gary R Maharaj||CEO||Sell||5,000||$28.03||$140,150.00|| |
|6/16/2017||Bryan K Phillips||SVP||Sell||1,226||$24.85||$30,466.10|| |
|6/9/2017||Joseph J Stich||VP||Sell||1,000||$25.31||$25,310.00|| |
|6/5/2017||Gary R Maharaj||CEO||Sell||2,702||$25.09||$67,793.18|| |
|4/3/2017||Gary R. Maharaj||CEO||Sell||584||$25.00||$14,600.00|| |
|3/6/2017||Joseph J. Stich||VP||Sell||1,000||$24.73||$24,730.00|| |
|12/22/2016||Charles W Olson||VP||Sell||1,201||$26.00||$31,226.00|| |
|12/8/2016||Charles W Olson||VP||Sell||3,699||$26.02||$96,247.98|| |
|12/5/2016||Joseph J Stich||VP||Sell||1,000||$23.97||$23,970.00|| |
|12/2/2016||Bryan K Phillips||SVP||Sell||1,264||$23.90||$30,209.60|| |
|11/25/2016||Charles W Olson||VP||Sell||500||$26.02||$13,010.00|| |
|11/7/2016||Gary R Maharaj||CEO||Sell||5,000||$25.22||$126,100.00|| |
|10/3/2016||Gary R. Maharaj||CEO||Sell||5,000||$29.55||$147,750.00|| |
|8/17/2016||Charles W Olson||VP||Sell||9,936||$28.98||$287,945.28|| |
|8/15/2016||Susan E. Knight||Director||Sell||1,548||$28.64||$44,334.72|| |
|8/1/2016||Charles W Olson||VP||Sell||12,500||$27.08||$338,500.00|| |
|6/14/2016||Bryan K Phillips||SVP||Sell||1,816||$23.44||$42,567.04|| |
|6/10/2016||Joseph J Stich||VP||Sell||1,000||$23.33||$23,330.00|| |
|5/27/2016||Susan E Knight||Director||Sell||1,001||$22.71||$22,732.71|| |
|3/4/2016||Timothy J Arens||VP||Sell||10,291||$18.43||$189,663.13|| |
|12/4/2015||Joseph J Stich||VP||Sell||1,000||$21.18||$21,180.00|| |
|9/4/2015||Joseph J Stich||VP||Sell||1,000||$23.57||$23,570.00|| |
|6/5/2015||Joseph J Stich||VP||Sell||1,000||$23.84||$23,840.00|| |
|5/22/2015||Bryan K Phillips||SVP||Sell||7,293||$25.25||$184,148.25|| |
|12/29/2014||Charles W Olson||VP||Sell||5,083||$21.98||$111,724.34|| |
|12/8/2014||Charles W Olson||VP||Sell||3,365||$21.66||$72,885.90|| |
|11/19/2014||Timothy J Arens||VP||Sell||10,330||$21.02||$217,136.60|| |
|5/8/2014||Susan Knight||Director||Buy||1,500||$20.36||$30,540.00|| |
|12/4/2013||Bryan Phillips||SVP||Sell||16,236||$22.95||$372,616.20|| |
|5/15/2013||Mark A Lehman||Insider||Sell||1,693||$26.55||$44,949.15|| |
|8/10/2012||Value Lp Starboard||Major Shareholder||Sell||257,560||$17.74||$4,569,114.40|| |
Headline Trends for Surmodics (NASDAQ:SRDX)
Latest Headlines for Surmodics (NASDAQ:SRDX)
Loading headlines, please wait.
Surmodics (SRDX) Chart for Sunday, October, 22, 2017